🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Perjeta ®

Found 53 matching trials

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

PHASE3

This is a randomized, double-blind, multicenter trial，parallel control desi...

Status

Completed

Location

Fudan University Cancer Hospital

Start Date

2020-11-23

Trial ID

NCT04629846

Treatments Being Tested

Trastuzumab QL1209 Pertuzumab Docetaxel surgery

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

PHASE3

This is a Phase IIIb, multinational, multicenter, randomized, open-label st...

Status

Completed

Location

Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Start Date

2022-07-05

Trial ID

NCT05415215

Treatments Being Tested

Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Pertuzumab IV Trastuzumab IV Trastuzumab Emtansine Investigator's Choice of Chemotherapy Surgery Radiotherapy

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

PHASE2

This study is being conducted in patients with newly diagnosed breast cance...

Status

Completed

Location

Columbia University Irving Medical Center

Start Date

2012-10

Trial ID

NCT01847001

Treatments Being Tested

Propranolol DOT imaging Paclitaxel Nab-paclitaxel Trastuzumab Pertuzumab Doxorubicin Cyclophosphamide Surgery Premedication Anti-nausea therapy Pegfilgrastim

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

PHASE1

This is a study to compare the similarity in Pharmacokinetics (PK) profile ...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-07-03

Trial ID

NCT07601620

Treatments Being Tested

HLX319 EU-Phesgo®

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

PHASE3

To compare the efficacy and safety of PERT-IJS (Proposed biosimilar Pertuzu...

Status

Terminated

Location

Chopda Medicare & Research Centre Pvt. Ltd,

Start Date

2025-01-06

Trial ID

NCT06038539

Treatments Being Tested

PERT-IJS plus trastuzumab, carboplatin and docetaxel Perjeta plus trastuzumab, carboplatin and docetaxel

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

PHASE2

This randomized, open-label, two-arm, multi-center, Phase II study will eva...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2012-02-17

Trial ID

NCT01491737

Treatments Being Tested

Pertuzumab Trastuzumab Aromatase Inhibitor Induction Chemotherapy

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

PHASE1

This trial is a single-center, single-dose, double-blind, parallel-group, r...

Status

Completed

Location

CRS Clinical Research Services Berlin GmbH

Start Date

2022-05-16

Trial ID

NCT05471648

Treatments Being Tested

420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection Perjeta (EU origin) 420 mg in 14 mL Injection Perjeta (US origin) 420 mg in 14 mL Injection

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

PHASE2

This is a Phase II, randomized, multicentre, multinational, open-label, cro...

Status

Completed

Location

Rocky Mountain Cancer Center - Lakewood (West)

Start Date

2018-12-19

Trial ID

NCT03674112

Treatments Being Tested

Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)Pertuzumab IV Trastuzumab IV

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

PHASE1

This randomized phase I/II trial studies the side effects of vaccine therap...

Status

Completed

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2014-02-05

Trial ID

NCT01922921

Treatments Being Tested

HER-2/neu Intracellular Domain Protein Laboratory Biomarker Analysis Pertuzumab Placebo Polysaccharide-K Trastuzumab

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

PHASE3

The purpose of this study is to compare the efficacy, safety, pharmacokinet...

Status

Completed

Location

Unique Hospital-Multispeciality & Resesarch Institute

Start Date

2022-09-26

Trial ID

NCT05283837

Treatments Being Tested

Pertuzumab (ZRC-3277)Pertuzumab (Perjeta®)

Previous Next